Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer.
Eur J Gynaecol Oncol
; 38(1): 76-79, 2017.
Article
en En
| MEDLINE
| ID: mdl-29767869
OBJECTIVE: To observe bevacizumab plus chemotherapy curative effect and safety for recurrent and metastatic cervical cancer. MATERIALS AND METHODS: Retrospective analysis of 30 recurrent and metastatic cervical cancer cases. The experimental group received beva- cizumab plus paclitaxel-, docetaxel-, and platinum-based chemotherapy. The control group received only chemotherapy. Curative effects were recorded after at least two treatment cycles; adverse reactions were recorded with every cycle. RESULTS: Experimental group patients were treated for an average 2.6 cycles. Compared to the control group, the experimental group effective rate (26.7%) was similar, disease control rate (73.7%) was significantly higher, and median survival time was three months longer. Bevacizumab-associated adverse reactions were bleeding, hypertension, and thrombosis/embolism; most were level 1 and 2 reactions. Adverse reactions in the two groups were not statistically different. CONCLUSIONS: The bevacizumab plus chemotherapy disease control rate for recurrent and metastatic cervical cancer is comparatively high, prolonging median survival; bevacizumab-associated adverse reactions are mild and tolerable.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Escamosas
/
Adenocarcinoma
/
Neoplasias del Cuello Uterino
/
Bevacizumab
/
Antineoplásicos Inmunológicos
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Eur J Gynaecol Oncol
Año:
2017
Tipo del documento:
Article
Pais de publicación:
Singapur